THERAPEUTIC CONTROL OF HYPERLIPIDEMIA IN THE PREVENTION OF CORONARY ATHEROSCLEROSIS - A REVIEW OF RESULTS FROM RECENT CLINICAL-TRIALS

[1] [Anonymous], 1970, JAMA, V214, P1303

[2] [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360

[3] [Anonymous], 1972, JAMA-J AM MED ASSOC, DOI [DOI 10.1001/JAMA.1972.03200070084015, 10.1001/jama.1972.03200070084015]

[4] [Anonymous], 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009

[5] REGRESSION AND PROGRESSION OF EARLY FEMORAL ATHEROSCLEROSIS IN TREATED HYPERLIPOPROTEINEMIC PATIENTS [J]. ANNALS OF INTERNAL MEDICINE, 1977, 86 (02) : 139 - 146

[6] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23): : 3233 - 3240

[7] EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY [J]. CIRCULATION, 1984, 69 (02) : 313 - 324

[8] BROWN MS, 1987, HARRISONS PRINCIPLES, P1650

[9] 15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) : 1245 - 1255

[10] ANTIATHEROGENIC EFFECT OF PROBUCOL UNRELATED TO ITS HYPOCHOLESTEROLEMIC EFFECT - EVIDENCE THAT ANTIOXIDANTS INVIVO CAN SELECTIVELY INHIBIT LOW-DENSITY-LIPOPROTEIN DEGRADATION IN MACROPHAGE-RICH FATTY STREAKS AND SLOW THE PROGRESSION OF ATHEROSCLEROSIS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7725 - 7729

[1] [Anonymous], 1970, JAMA, V214, P1303

[2] [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360

[3] [Anonymous], 1972, JAMA-J AM MED ASSOC, DOI [DOI 10.1001/JAMA.1972.03200070084015, 10.1001/jama.1972.03200070084015]

[4] [Anonymous], 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009

[5] REGRESSION AND PROGRESSION OF EARLY FEMORAL ATHEROSCLEROSIS IN TREATED HYPERLIPOPROTEINEMIC PATIENTS [J]. ANNALS OF INTERNAL MEDICINE, 1977, 86 (02) : 139 - 146

[6] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23): : 3233 - 3240

[7] EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY [J]. CIRCULATION, 1984, 69 (02) : 313 - 324

[8] BROWN MS, 1987, HARRISONS PRINCIPLES, P1650

[9] 15 YEAR MORTALITY IN CORONARY DRUG PROJECT PATIENTS - LONG-TERM BENEFIT WITH NIACIN [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (06) : 1245 - 1255

[10] ANTIATHEROGENIC EFFECT OF PROBUCOL UNRELATED TO ITS HYPOCHOLESTEROLEMIC EFFECT - EVIDENCE THAT ANTIOXIDANTS INVIVO CAN SELECTIVELY INHIBIT LOW-DENSITY-LIPOPROTEIN DEGRADATION IN MACROPHAGE-RICH FATTY STREAKS AND SLOW THE PROGRESSION OF ATHEROSCLEROSIS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7725 - 7729